Journal List > Ewha Med J > v.37(Suppl) > 1058626

TOOLS
Choi, Park, Ko, Lee, Choi, and Kim: Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis
Case Report

The Ewha Medical Journal 2014; 37(Suppl): S5-S9.

Published online: 24 December 2014

DOI: https://doi.org/10.12771/emj.2014.37.S.S5

Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis

Sang Il Choi, Sun Seob Park, Eun Jeong Ko, Si Won Lee, Mihong Choi, Kiwon Kim

Department of Internal Medicine, National Cancer Center, Goyang, Korea.

Corresponding author: Kiwon Kim. Department of Internal Medicine, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea. Tel: 82-31-920-1679, Fax: 82-31-920-0209, kiwonkim@ncc.re.kr

Received 9 May 2014       Accepted 1 July 2014

Copyright © 2014, The Ewha Medical Journal

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Small cell lung cancer is primarily treated with chemotherapy. For patients with end-stage renal disease (ESRD), systemic chemotherapy is often challenging since renal excretion of chemotherapeutic agents might be decreased due to impaired renal function, leading to increased toxicity. No consensus is made so far regarding appropriate dosage and combination of chemotherapeutic agents for patients on hemodialysis. We report two cases of chemotherapy without significant toxicity in small cell lung cancer patients who were on hemodialysis for ESRD.

Keywords: Small cell lung carcinoma, Drug therapy, Kidney failure, chronic, Renal dialysis

Figures and Tables

Fig. 1
Positron emission tomography at the time of initial diagnosis (A), after 3 cycles of treatment (B), after 6 cycles of treatment (C), and 6 weaks after the treatment completion (D).
emj-37-S5-g001
Fig. 2
Treatment course from the time of diagnosis of case 2. PR, partial response; PD, progression of disease.
emj-37-S5-g002

References

1. Na SY, Sung JY, Chang JH, Kim S, Lee HH, Park YH, et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol. 2011; 33:121–130.
2. Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, et al. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol. 2010; 66:813–817.
3. Kim DM, Kim HL, Chung CH, Park CY. Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease. Korean J Intern Med. 2009; 24:73–75.
4. Takezawa K, Okamoto I, Fukuoka M, Nakagawa K. Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J Thorac Oncol. 2008; 3:1073–1075.
5. Tanizawa K, Fukunaga K, Okumura N, Sugimura M, Tanaka E, Hajiro T, et al. Successful chemotherapy for small-cell lung cancer in an elderly patient undergoing continuous ambulatory peritoneal dialysis. Intern Med. 2010; 49:1179–1183.
6. Hiraike M, Hiraki Y, Misumi N, Hanada K, Tsuji Y, Kamimura H, et al. Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemother Pharmacol. 2012; 69:845–848.
7. Murakami K, Akutsu Y, Miyazawa Y, Shuto K, Shiratori T, Uesato M, et al. A case of small-cell esophageal cancer with chronic renal failure undergoing hemodialysis safely treated with cisplatin and etoposide. Esophagus. 2011; 8:209–215.
8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7:1748–1756.
9. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010; 21:1395–1403.
10. Schmittel A, Sebastian M, Fischer von, Martus P, Gauler TC, Kaufmann C, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011; 22:1798–1804.
TOOLS
Similar articles